Talk about auction fever. The new Mustang Dark Horse SC is supposed to give buyers some of the GTD’s goodies without the supercar price, but the first car has just been sold at auction for a ...

The Mustang Dark Horse SC features a 5.2-liter supercharged V8 and track-focused upgrades. Track Pack adds carbon fiber wheels, carbon-ceramic brakes, and up to 620 pounds downforce. Interior options ...

Ford just unveiled the new Mustang Dark Horse SC, framed as the “most advanced, powerful, and track-capable Dark Horse yet.” The Mustang Dark Horse SC features a long list of race-ready components and ...

View post: Why the Iran War Could Take Us Back To The ’70s Ford will no longer include a free frunk in the 2026 Mustang Mach-E. The change aims to lower starting prices, as most buyers didn't use the ...

The Ford Mustang debuted in 1964. The iconic Ford Mustang might well have entered the world branded a Cougar instead. But it wasn’t to be. The galloping horse logo won out, and the rest, as they say, ...

WORCESTER, Mass., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical ...

Ford is testing a new electrified Mustang that may not be as electric as it seems. The next-gen Mustang is apparently already in development. Here’s what we know about it so far. Is Ford launching an ...

Prime Minister Narendra Modi inaugurated the Bio Ethanol Private Limited Plant at Numaligarh Refinery and laid the foundation stone for a new Polypropylene Plant.The projects mark a significant step ...

Bio-PE is derived from biological sources like sugarcane instead of petroleum. The manufacturing process begins with extracting ethanol from sugarcane, which is then dehydrated to produce ethylene, ...

Shares of Mustang Bio (NASDAQ:MBIO) jumped on Monday after the company said that the U.S. FDA has granted orphan drug status to its CAR T-cell therapy, MB-101, for the treatment of astrocytoma and ...

The MarketWatch News Department was not involved in the creation of this content. In an ongoing Phase 1 trial published in Nature Medicine, MB-101 was well-tolerated and 50% of patients achieved ...